Cimetidine Hydrochloride

CHEMBL1201051 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

288.8 g/mol

LogP

—

Phase

4

The hydrochloride salt formulation of cimetidine is used for parenteral administration in hospitalized patients requiring acid suppression. It shares the same H2 receptor blocking activity and drug interaction profile as the oral form. Gynecomastia and other anti-androgenic effects have been noted with higher doses due to its weak androgen receptor antagonism.

分子量

288.8000 g/mol

TPSA

114.00 Å²

作用機序

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CN/C(=N\CCSCc1nc[nH]c1C)NC#N.Cl

InChI

InChI=1S/C10H16N6S.ClH/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11;/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14);1H

Molecular Formula

C10H17ClN6S

HBD / HBA

4 / 4

回転可能結合数

7

重原子数

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The hydrochloride salt formulation of cimetidine is used for parenteral administration in hospitalized patients requiring acid suppression. It shares the same H2 receptor blocking activity and drug interaction profile as the oral form. Gynecomastia and other anti-androgenic effects have been noted with higher doses due to its weak androgen receptor antagonism.

Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.

Yes, Cimetidine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201051. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 50963. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Cimetidine Hydrochloride PillFYIで

構造

クイックデータ

分子式: C10H17ClN6S

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.